Uncategorized Archives - Vista Partners LLC

An Applied $7.5 Billion Signal From the Heartland -( $APLD $CRWV $GOOG )

by John F. Heerdink, Jr. 5 days ago 214Views 0Likes

Applied Digital’s (NASDAQ: APLD) latest mega-lease reads less like a data-center contract and more like a sovereign-infrastructure plotline for the AI age, and that is precisely where Seven Boson Group’s sovereign AI lab vision strides onto the stage. A $7.5 Billion Signal From…

From Antibodies to Atoms: Inside the Telix–Regeneron Tie-Up and NAYA’s Radiopharma Supply-Chain Fortress -( $REGN $IBB $XBI )

by John F. Heerdink, Jr. April 15, 2026 274Views 0Likes

Telix, Regeneron (REGN), and NAYA Therapeutics are turning radiopharmaceuticals into one of Wall Street’s more serious new growth stories—while quietly building the kind of supply-chain moats that would make an oil baron blush. Telix and Regeneron: A $2 Billion Bet on “Hot”…

Australia’s Richest Person Just Got A Reality Check: When Iron Ore Royalties Must Be Shared -( $MP $BHP $FMG $RIO )

by John F. Heerdink, Jr. April 15, 2026 307Views 0Likes

Australia’s richest person is discovering that in the Pilbara, even billion‑dollar iron ore cheques come with fine print – and a judge. Royalty Rivers Meet Legal Dams Gina Rinehart, long crowned Australia’s richest individual with an estimated fortune north of 40 billion…

From Ringtones to Terabits: Nokia Quietly Reboots Its Wall Street Story -( $BAC $NOK )

by John F. Heerdink, Jr. April 14, 2026 145Views 0Likes

Nokia’s (NOK) stock is trading back in the conversation — only this time, it’s not about ringtones but terabits. BofA Rediscovers Nokia, This Time in Terabytes Bank of America (BAC) has upgraded Nokia to Buy from Neutral and lifted its price target to 10.70…

The Bubble, The Billionaire, and a Brutal Future?: Robert Friedland’s Case Against Complacency -( $SPY $QQQ $DIA )

by John F. Heerdink, Jr. April 6, 2026 280Views 0Likes

The illusion of comfort that has defined much of American life in recent years is colliding with a far harsher reality taking shape beneath the surface. Robert Friedland, the influential billionaire investor and mining magnate, has been sounding the alarm that many…

How to Stop Scaring Off Family Offices: A Survival Guide for CEOs

by John F. Heerdink, Jr. April 3, 2026 92Views 0Likes

Family offices are not just another line on the capital-raising target list; they are slow-moving, high-conviction decision engines run by people whose last name is on both the door and the check. Approaching them like just another fund is why most pitches…

Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI )

by John F. Heerdink, Jr. April 2, 2026 277Views 0Likes

Big Pharma spent the week shopping again, snapping up a fresh crop of biotech and pharmaceutical names in deals that underscore one message: pipelines are the new gold, and the majors are still happily paying spot prices. From autoimmune bets to allergy…

When Bangles Meet Bankers: Inside India’s Glittering Gold-Loan Boom -( $GLD )

by John F. Heerdink, Jr. March 19, 2026 329Views 0Likes

India’s gold-backed lending boom is turning family heirlooms into the country’s most hardworking asset class, as households and small businesses increasingly march into bank branches with bangles instead of balance sheets. Rising gold prices, looser lending rules, and a vast, underutilized stockpile…

AI or Die Trying: Why Lifelong Learning Is Wall Street’s Quiet Bull Market -( $DIA $QQQ $SPY )

by John F. Heerdink, Jr. March 10, 2026 306Views 0Likes

For decades, markets rewarded management teams that could master a strategy, stick to it, and talk about it in perfect bullet points. Today, investors are quietly rerating a different skill: the ability to discard that strategy on demand when the world—and the…

Wegovy Goes Online, Insulin Goes Tubeless: Why Metabolic Care Suddenly Looks Sexy -( $HIMS $MODD $NVO )

by John F. Heerdink, Jr. March 9, 2026 318Views 0Likes

Hims & Hers (HIMS) just turned a courtroom drama into a growth story and its stock has flown +40% higher today, and a little-known insulin pump maker may be quietly scripting the sequel in metabolic health. Hims & Hers: From GLP-1 Outlaw…

Uncategorized

Your Guide To Staying Informed In The Markets